iNNOVATE™: Prespecified secondary endpoint, IMBRUVICA® + rituximab vs rituximab

IMBRUVICA® + rituximab vs rituximab1-3

These data are not included in the Prescribing Information for IMBRUVICA®

Long-term data from the final analysis, with overall follow-up of 63 months; median follow-up was 50 months1,2

Overall Survival

Median overall survival was not reached for either treatment arm. With an overall follow-up of 63 months, 47% of patients randomized to the placebo + rituximab arm crossed over to receive IMBRUVICA®. 9 (12%) patients on IMBRUVICA® + rituximab and 10 (13.3%) patients on placebo + rituximab had died.1

  • Crossover was allowed in the study. At least one minimum criteria per the IWWM-2 is required for a patient who had IRC-confirmed disease progression or symptomatic disease to be eligible for next-line IMBRUVICA® treatment.3